Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Receivables (2020 - 2025)

PROCEPT BioRobotics has reported Receivables over the past 6 years, most recently at $83.5 million for Q4 2025.

  • Quarterly results put Receivables at $83.5 million for Q4 2025, changed 0.04% from a year ago — trailing twelve months through Dec 2025 was $83.5 million (changed 0.04% YoY), and the annual figure for FY2025 was $83.5 million, changed 0.04%.
  • Receivables for Q4 2025 was $83.5 million at PROCEPT BioRobotics, down from $84.5 million in the prior quarter.
  • Over the last five years, Receivables for PRCT hit a ceiling of $84.5 million in Q3 2025 and a floor of $4.5 million in Q4 2021.
  • Median Receivables over the past 5 years was $41.5 million (2023), compared with a mean of $43.8 million.
  • Biggest five-year swings in Receivables: surged 242.11% in 2022 and later increased 0.04% in 2025.
  • PROCEPT BioRobotics' Receivables stood at $4.5 million in 2021, then surged by 242.11% to $15.3 million in 2022, then skyrocketed by 216.76% to $48.4 million in 2023, then soared by 72.6% to $83.5 million in 2024, then rose by 0.04% to $83.5 million in 2025.
  • The last three reported values for Receivables were $83.5 million (Q4 2025), $84.5 million (Q3 2025), and $80.8 million (Q2 2025) per Business Quant data.